• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Page 3 > News & stories

Statements

Page 3 > News & stories

Statements

filters

Type & Disease
Topic
Location
Date Range
Type & Disease

By Type

news type

By Disease

diseases

Topic

By Topic

topic type

Location

By Location

location-news

Date Range

By Year

date range filter – slider
1999 — 2026

Results

No results found. Please try using different filter option(s).

In the media
8 Jul 2026

No medicine for dengue yet, Serum Institute’s new treatment is headed for global trials

The Print
Viewpoints
3 Aug 2026

A new chapter for African medical innovation

Nature Africa
Daily Nation logo
In the media
1 Aug 2026

End of painful injections as Kenya set to adopt new 14-day Kala-azar treatment

Daily Nation
New Vision logo
In the media
30 Jul 2026

WHO approves new shorter, less painful Kala-azar treatment for East Africa

New Vision
Viewpoints
30 Jul 2026

Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases

Stat News
Leishmaniasis patient Monica Lomoler carrying a bunch of firewood
Press releases
29 Jul 2026

WHO recommends new, better and safer treatment regimens for leishmaniasis

Press releases
27 Jul 2026

DNDi leadership to change in 2027

Stories
16 Jul 2026

Annie Liang: How students’ advocacy helped bring mycetoma out of the shadows

Publications
16 Jul 2026

DNDi 2025 Annual Report

The Telegraph
In the media
15 Jul 2026

Dengue outbreak complicates Bangladesh measles crisis response

The Telegraph
Laboratory of Medicinal and Computational Chemistry (LQMC), São Paulo University USP, São Carlos Campus, São Paulo Brazil.
Press releases
13 Jul 2026

DNDi welcomes continued GHIT support for collaboration on dengue and Zika virus drug discovery with Eisai and new partner, the Japan Institute for Health Security 

Chepokarial Rubben attentively cares for her five-year-old son, Romanu Kiptoo, at the kala-azar ward of Kacheliba Sub-County Referral Hospital in West Pokot County, Kenya. She gently soothes him, offering comfort as he endures the painful treatment for kala-azar.
Press releases
13 Jul 2026

DNDi welcomes GHIT support to advance novel oral drug candidate for leishmaniasis, accelerating progress towards elimination goals

Scientific articles
9 Jul 2026

Consensus framework for developing a target product profile of real-time PCR in Chagas disease therapeutic monitoring

PLOS Neglected Tropical Diseases
The Indian Express logo
In the media
9 Jul 2026

Serum Institute of India ties up with DNDi for Phase III trial of dengue therapy

The Indian Express
Press Releases Translations
8 Jul 2026

Brasil, Malásia e Tailândia estão prestes a iniciar ensaio clínico para testar tratamento promissor contra a dengue desenvolvido pelo Instituto Serum da Índia

Press Releases Translations
8 Jul 2026

Brasil, Malasia y Tailandia están a punto de iniciar ensayos clínicos para probar un prometedor tratamiento contra el dengue desarrollado por el Serum Institute of India

loading
Loading...
Statements
24 May 2023

DNDi interventions at the 76th World Health Assembly

Statements
19 May 2023

DNDi’s briefing note for 76th World Health Assembly

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Statements
14 Nov 2022

DNDi’s response to the Public consultation related to the WHA 75.8

Statements
29 Sep 2022

DNDi intervention at the Intergovernmental Negotiating Body second round of public hearings

Statements
18 Jul 2022

DNDi‘s comments on the working draft of the WHO CAll for the consideration of the INB at its second meeting

Statements
23 Jun 2022

DNDi Executive Director Dr Bernard Pécoul’s address to the Kigali Summit on Malaria and NTDs

Statements
16 Jun 2022

DNDi written comments on the Intergovernmental Negotiating Body White Paper

Statements
15 Jun 2022

DNDi endorses consensus statement on gender-responsive international instrument for pandemic prevention, preparedness, and response

Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Statements
18 Apr 2022

DNDi‘s initial comments on the Intergovernmental Negotiating Body deliberations

Statements
12 Apr 2022

DNDi intervention at the Intergovernmental Negotiating Body first round of public hearings

Statements
1 Feb 2022

DNDi briefing note for the 150th session of the WHO Executive Board

1 2 … 6 ›

Connect and share

Follow us on social media to stay updated and help us share the stories of neglected patients.  

Linkedin Instagram Facebook Youtube
EM PORTUGUÊS
EN ESPAÑOL
Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license